ESTAのチャート
ESTAの企業情報
| symbol | ESTA |
|---|---|
| 会社名 | Establishment Labs Holdings Inc （エスタブリッシュメント・ラボズ・ホ―ルディングス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Industrial Specialties |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 Establishment Labs Holdings Inc. is a medical technology and aesthetics company that is focused on patient safety and aesthetic outcomes and also in the breast aesthetics and reconstruction market. The Company is engaged in the designing developing manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. Its line of silicone gel-filled breast implants branded as MotivaImplants is the centerpiece of its MotivaImagine medical technology platform. The Company’s MotivaImplants are sold in over 60 countries. エスタブリッシュメント・ラボズ・ホ―ルディングスはコスタリカの医療機器メ―カ―持株会社。子会社を通じて、美容整形手術、再建整形手術、美容皮膚科治療のための医療機器の設計・製造・販売に従事する。同社は「Motiva Implants」の商標名でシリコン・インプラントを製造、また3D画像のシミュレ―ションシステムも提供する。 Establishment Labs Holdings Inc. is a global medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company's direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs' product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. |
| 本社所在地 | Building B15 and 25 Coyol Free Zone Alajuela CRI |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 41548 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.establishmentlabs.com |
| nasdaq_url | https://www.nasdaq.com/symbol/esta |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -17.35600 |
| 終値（lastsale） | 23.58 |
| 時価総額（marketcap） | 482714197.2 |
| 時価総額 | 時価総額（百万ドル） 485.98960 |
| 売上高 | 売上高（百万ドル） 47.66000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 499.57160 |
| 当期純利益 | 当期純利益（百万ドル） -29.69700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Establishment Labs Holdings Inc revenues increased 83% to $28.5M. Net loss decreased 30% to $11.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Realized Gain/Loss on Derivative-Hedging increase from $4.2M (expense) to $4.5M (income) Initial public offering expenses decrease from $1.6M (expense) to $0K. |
ESTAのテクニカル分析
ESTAのニュース
Establishment Labs: More Constructive, But Not At 10x Sales 2023/03/03 17:44:08 Seeking Alpha
Establishment Labs'' top-line growth was commendable with upsides in key markets, especially Brazil. Click here to read my most recent analysis of ESTA.
ROSEN, A LEADING LAW FIRM, Encourages Establishment Labs Holdings Inc. Investors with Losses to Inquire About Securities Class Action Investigation - ESTA 2023/03/01 20:14:00 PR Newswire
NEW YORK, March 1, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Establishment Labs Holdings Inc. (NASDAQ: ESTA) resulting from allegations that the Company may have…
Establishment Labs GAAP EPS of -$0.55 beats by $0.13, revenue of $43.81M beats by $0.73M 2023/02/27 21:03:58 Seeking Alpha
Establishment Labs press release (ESTA): Q4 GAAP EPS of -$0.55 beats by $0.13.Revenue of $43.81M (+24.1% Y/Y) beats by $0.73M.Fourth and final module submitted to U.S. FDA for…
Establishment Labs Submits Module Four to U.S. FDA for Premarket Approval of Motiva and Reports Record Fourth Quarter and Full Year 2022 Financial Results 2023/02/27 21:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted the fourth and final module of its modular submission to the FDA for premarket approval of Motiva Implants® in the United States. The company also provided unaudited financial results for the fourth quarter and full year ended December 31, 2022
Establishment Labs Hldgs Earnings Preview 2023/02/24 18:02:13 Benzinga
Establishment Labs Hldgs (NASDAQ: ESTA ) is set to give its latest quarterly earnings report on Monday, 2023-02-27. Here''s what investors need to know before the announcement. Analysts estimate that Establishment Labs Hldgs will report an earnings per share (EPS) of $-0.68. Establishment Labs Hldgs bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, … Full story available on Benzinga.com
Establishment Labs: More Constructive, But Not At 10x Sales 2023/03/03 17:44:08 Seeking Alpha
Establishment Labs'' top-line growth was commendable with upsides in key markets, especially Brazil. Click here to read my most recent analysis of ESTA.
ROSEN, A LEADING LAW FIRM, Encourages Establishment Labs Holdings Inc. Investors with Losses to Inquire About Securities Class Action Investigation - ESTA 2023/03/01 20:14:00 PR Newswire
NEW YORK, March 1, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Establishment Labs Holdings Inc. (NASDAQ: ESTA) resulting from allegations that the Company may have…
Establishment Labs GAAP EPS of -$0.55 beats by $0.13, revenue of $43.81M beats by $0.73M 2023/02/27 21:03:58 Seeking Alpha
Establishment Labs press release (ESTA): Q4 GAAP EPS of -$0.55 beats by $0.13.Revenue of $43.81M (+24.1% Y/Y) beats by $0.73M.Fourth and final module submitted to U.S. FDA for…
Establishment Labs Submits Module Four to U.S. FDA for Premarket Approval of Motiva and Reports Record Fourth Quarter and Full Year 2022 Financial Results 2023/02/27 21:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted the fourth and final module of its modular submission to the FDA for premarket approval of Motiva Implants® in the United States. The company also provided unaudited financial results for the fourth quarter and full year ended December 31, 2022
Establishment Labs Hldgs Earnings Preview 2023/02/24 18:02:13 Benzinga
Establishment Labs Hldgs (NASDAQ: ESTA ) is set to give its latest quarterly earnings report on Monday, 2023-02-27. Here''s what investors need to know before the announcement. Analysts estimate that Establishment Labs Hldgs will report an earnings per share (EPS) of $-0.68. Establishment Labs Hldgs bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, … Full story available on Benzinga.com
Establishment Labs to Present at the Jefferies Healthcare Conference 2022/06/06 12:00:00 Business Wire
SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 am Eastern Time. A live webcast of the presentation will
Establishment Labs GAAP EPS of -$0.24 beats by $0.13, revenue of $38.45M beats by $3.19M 2022/05/09 20:23:37 Seeking Alpha
Establishment Labs press release (ESTA): Q1 GAAP EPS of -$0.24 beats by $0.13.Revenue of $38.45M (+26.9% Y/Y) beats by $3.19M.2022 revenue guidance of $155 million to $165 million vs
Establishment Labs Reports Record First Quarter 2022 Financial Results 2022/05/09 20:00:00 Wallstreet:Online
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the first quarter ended March 31, 2022. First Quarter Highlights and Outlook Strong momentum with first quarter worldwide sales of $38.5 million, an increase
Establishment Labs to Announce First Quarter 2022 Financial Results on May 9 2022/04/28 12:00:00 Business Wire
SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2022 after the market closes on Monday, May 9, 2022, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S